We further evaluate the effect of APM on tumor cells in RCC bone metastases by reclustering malignant cells based on epithelial markers (Krt8 and Krt18) (Figure S4A, Supporting Information), identifying four subtypes (Tumors 1, 2, 3, and 4) with different proportions between the APM‐treated and APM‐naïve groups (Figure3A–C; Figure S4B, Supporting Information). This evidence concerns the gene KRT18 and renal cell carcinoma.